Service Hotline: +86 4006196063
MyCare five antipsychotic products ( clozapine, olanzapine, quetiapine, total aripiprazole and total risperidone) are included in a series of exclusive programs [MyCare blood concentration monitoring] jointly undertaken by our company and Saladax Company of the United States. |
It is of great reference value to understand the relationship between "dose-blood concentration-efficacy" through plasma concentration monitoring of antipsychotics. |
MyCare provides a new testing tool for clinical precision therapy. Relying on the automatic biochemical platform, it can realize rapid, simple and accurate testing of the plasma concentration of antipsychotics. |
Effectively help clinicians formulate individualized medication dosage for each patient and realize individual-based treatment for each patient. |
The universal automatic biochemistry analyzer can inspect samples upon arrival without pre-treatment. No additional instrument is needed.
The testing only takes 10 minutes, and real time results can be achived on the same day.
Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) published the Consensus Guidelines for Psychiatric Medication Monitoring (2017 edition) to clarify the necessity of TDM for antipsychotics and recommend the reference scope of treatment.
Saladax has the world's leading detection technology and tumor chemotherapy drug monitoring product portfolio, and its intellectual property covers the major antipsychotic prescription drugs worldwide, making Saladax a leading position in the field of antipsychotic drug testing.
Relevant national or international intellectual property patents have been obtained for clozapine, olanzapine, risperidone and aripiprazole, thus ensuring the testing quality. (Aripiprazole hapten and its application in immunoassay: CN 104822660 A; Olanzapine hapten: CN 104854110 A; Olanzapine hapten: CN 104854110 A; antibodies of olanzapine hapten and their usage: CN 104755093 A; risperidone immunoassay: WO 2011/115733 A1; Clozapine immunoassay: WO 2012/161938 A1).
Shanghai ICP Filing No.06018982-5
COPYRIGHT @2019-2022 Fosun Diagnostics (Shanghai) Co., Ltd.
Shanghai PSB Filing No.11010808888
No. of Qualification Certificate for Medicine Trading Services on the Internet:
(Shanghai)-Non-operating-2018-0046
